Prostate cancer is one of the most common cancers affecting men. The prognosis for prostate cancer is generally very good. It is often slow growing making aggressive treatment unnecessary. The challenge with early detection is to identify patients with fast growing or aggressive cancers who would benefit from treatment while avoiding over detection of slow growing cancer.
In this Guidelines Side-by-Side comparison, we look at the latest clinical practice guidelines from the American Urological Association (AUA)/Society of Urologic Oncology (SUO), the National Comprehensive Cancer Network (NCCN), and the European Association of Urology (EAU)/European Association of Nuclear Medicine (EANM)/European Society for Radiotherapy and Oncology (ESTRO) on early detection of prostate cancer.
| Item | Early Detection of Prostate Cancer: AUA/SUO Guideline (2026) | NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection | EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer |
|---|---|---|---|
| Authoring Organization | American Urological Association and Society of Urologic Oncology | National Comprehensive Cancer Network | European Association of Urology, European Association of Nuclear Medicine, and European Society for Radiotherapy and Oncology |
| Publication Date | February 2026 | February 2026 | April 2026 |
| Graded Recommendations | Yes | Yes | Yes |
| Uses GRADE | Yes | No, uses NCCN categories of evidence and consensus | No, uses modified level of evidence/strength of recommendation for Oxford Centre for Evidence-based Medicine Levels of Evidence |
| Links | Overview / Full Text | Full Text | Overview / Full Text |
Guideline Scope
- Both the AUA and NCCN guidelines focus on aiding in early detection of prostate cancer. They do not make recommendations regarding the management of prostate cancer.
- The EAU/EANM/ESTRO guideline is comprehensive with recommendations for screening and early detection, as well as, staging, management, and surveillance of prostate cancer.
Shared Decision Making
- All three guidelines emphasize the importance of shared clinical decision making before screening with serum PSA.
Age to Begin Screening
- All three guidelines recommend screening for prostate cancer begin between the ages of 40 and 50 years depending on individual risk factors with higher risk individuals beginning screening at age 40 and lower risk at age 50.
- The age to begin early screening, according to specific risk factors, varies among the guidelines with the AUA and NCCN being pretty closely aligned. These societies have also written their recommendations with more flexibility to tailor the timing to the individual patient by giving age ranges for early screening.
- The EAU/EANM/ESTRO provides the most specific recommendation with most men beginning screening at age 50, men with family history of prostate cancer and men of African descent beginning at age 45, and men with breast cancer gene 2 (BRCA2) mutations beginning at age 40.
Screening Interval
- The AUA and NCCN recommend screening every 2 to 4 years, taking into consideration patient age.
- In addition the NCCN considers baseline PSA levels when determining when to repeat screening.
- The EAU/EANM/ESTRO has more stringent guidelines for follow-up PSA testing every 2 years depending on initial PSA level and age, with individuals at low-risk not needing to follow-up for 8 years.
- The NCCN recommends patients 75 years or older with PSA less than 4ng/mL only repeat testing if they are very healthy and those with a PSA of 4 ng/mL or higher and/or a very suspicious digital rectal examination (DRE) undergo further evaluation.
Discontinuing Screening
- All three guidelines recommend considering life expectancy and general health when deciding if screening can be discontinued.
- The AUA is non-specific.
- NCCN recommends discontinuing screening with life expectancy less than 10 years and notes that screening is unlikely to benefit men with life expectancy that is less than 10 to 15 years.
- The EAU/EANM/ESTRO guideline agrees that men with a life expectancy of less than 15 years are unlikely to benefit from screening.
Elevated PSA
- The AUA recommends that PSA velocity, how much PSA increased between tests, not be used alone to determine if additional testing is needed.
- All three guidelines have recommendations for repeat PSA testing before proceeding with further evaluation.
- The NCCN and EAU/EANM/ESTRO both recommend PSAs between 3 or 4 and up to 10 ng/mL may be repeated before further investigation. The EAU/EANM/ESTRO guideline adds that this is for asymptomatic men with a normal DRE.
- The EAU/EANM/ESTRO guideline recommends asymptomatic men who have a normal DRE with PSA between 3 and 20 ng/mL undergo further evaluation to determine if a biopsy should be done.
- The NCCN also has recommendations for younger people with elevated PSA for their age and patients with PSA below 3 ng/mL. They also recommend that anyone with an elevated PSA and abnormal DRE have a prostate biopsy done to further evaluate.
Comparison of Recommendations
| Type | AUA | NCCN | EAU/EANM/ESTRO |
|---|---|---|---|
| Shared Decision Making | Shared clinical decision making is recommended when considering prostate cancer screening. | Shared clinical decision making with discussion of the harms and benefits for screening is recommended for men, transgender and gender diverse individuals who have a prostate. | Do not subject men to prostate-specific antigen (PSA) testing without counselling them onthe potential risks and benefits. |
| Age to Begin Screening | May begin prostate cancer screening with serum PSA in patients between the ages of 45 and 50 years. Begin prostate cancer screening at the age of 40 to 45 years in high risk patients: Black race; Germline mutations; Strong family history of prostate cancer. | Begin PSA testing at age 45. May begin early PSA testing at the age of 40 years in high risk patients: black race; certain germline mutations; concerning family or personal history of prostate cancer. | Offer early PSA testing to well-informed men at elevated risk of having PCa: men from 50 years of age; men from 45 years of age and a family history of PCa; men of African descent from 45 years of age; men carrying breast cancer gene 2 (BRCA2) mutations from 40 years of age. |
| Screening Interval | Patients aged 50 to 69 years should be screened for prostate cancer every two to four years. | Offer a risk-adapted strategy based on PSA level and risk level with repeat testing every two to four years for people with average risk: PSA level less than 1 ng/mL. Repeat testing every one to two years for people at high risk with: PSA no higher than 3 ng/mL and a normal DRE. Repeat testing every one to two years for patients with average risk and: PSA between 1 to 3 ng/mL. Patients 75 years or older with PSA less than 4 ng/mL and normal DRE may discontinue screening. For very healthy patients who choose to continue screening, repeat testing can be done every one to three years. For those with PSA 4 ng/mL or more and/or a DRE that is very suspicious further investigation is warranted. | Offer a risk-adapted strategy (based on initial PSA level), with follow-up intervals of two yearsfor those initially at risk:men with a PSA level of > 1 ng/mL at 40 years of age; men with a PSA level of > 2 ng/mL at 60 years of age; Postpone follow-up up to eight years in those not at risk. |
| When to Discontinue PSA Testing | Consider patient preferences, age, prostate cancer risk, general health and life expectancy when deciding how often to re-screen for prostate cancer or to discontinue screening. | Consider patient life expectancy, those with life expectancy of less than 10 to 15 years are unlikely to benefit from screening. Discontinue screening for patients with life expectancy of less than 10 years. | Stop early diagnosis of PCa based on life expectancy and performance status; men who have a life-expectancy of less than fifteen years are unlikely to benefit. |
| Elevated PSA | Repeat PSA before considering further evaluation with biomarker testing, MRI, or biopsy. Increased PSA levels compared to baseline should not be the only indication for further evaluation with biomarker testing, MRI, or biopsy. | For PSA between 4 to 10 ng/mL, repeat PSA. Young people with high PSA for age may need to be evaluated further. Patients with PSA less than 3 ng/mL should be evaluated for benign disease with a repeat PSA and DRE. Biopsy is indicated for patients with elevated PSA and abnormal DRE. | In asymptomatic men with a prostate-specific antigen (PSA) level between 3 and 10 ng/mL and a normal digital rectal examination (DRE), repeat the PSA test prior to further investigations. In asymptomatic men with a PSA level between 3 and 20 ng/mL and a normal DRE, use one of the following tools for biopsy indication: magnetic resonance imaging of the prostate; risk-calculator, provided it is correctly calibrated to the population prevalence; an additional serum, urine biomarker test. |
Check out our other urology content and sign up for alerts to stay informed on the latest published clinical guidelines and articles.